Autopsy and Case Reports
http://autopsyandcasereports.org/article/doi/10.4322/acr.2016.035
Autopsy and Case Reports
Article / Autopsy Case Report

Amyloidosis: an unusual cause of portal hypertension

Vilma Takayasu, Lorena Silva Laborda, Raquel Bernardelli, Henrique Trombini Pinesi, Marilia Polo Minguete e Silva, Viviane Chiavelli, Angélica Braz Simões, Aloisio Felipe-Silva

Downloads: 82
Views: 1254

Abstract

Amyloidosis comprises a group of diseases that occurs in five to nine cases per million patients per year worldwide irrespective of its classification. Although the hepatic involvement in primary amyloidosis is frequent, the clinical manifestations of liver amyloidosis are mild or even absent. The authors report the case of an aged man who complained of diffuse abdominal pain and marked weight loss and presented clinical signs of hepatopathy. Clinical workup revealed portal hypertension with ascites, hemorrhoids, and esophageal varices. The laboratory tests showed the cholestatic pattern of liver enzymes, hyperbilirubinemia, renal insufficiency and massive proteinuria accompanied by the presence of serum pike of monoclonal lambda light chain protein. The outcome was unfavorable, and the patient died. The autopsy findings revealed the diagnosis of amyloidosis predominantly involving the liver and kidneys. The bone marrow examination demonstrated the deposition of amyloid material associated with clonal plasma cells infiltration. The authors call attention to portal hypertension as a rare manifestation of primary amyloidosis. Meanwhile, this diagnosis should be taken into account whenever the hepatopathy is accompanied by laboratory abnormalities consistent with hepatic space-occupying lesions concomitantly with other organs involvement. In the case reported herein, kidney involvement was also present with renal failure, massive proteinuria with monoclonal serum gammopathy, what reinforced the diagnostic possibility of primary amyloidosis.

Keywords

Amyloidosis, Liver Diseases, Hypertension, Portal, Multiple myeloma

References

1. Glenner GG. Amyloid deposits and amyloidosis. The beta-fibrilloses (first of two parts). N Engl J Med. 1980;302(23):1283-92. http://dx.doi.org/10.1056/NEJM198006053022305. PMid:6154243.

2. Merlini G, Comenzo RL, Seldin DC, Wechalekar A, Gertz MA. Immunoglobulin light chain amyloidosis. Expert Rev Hematol. 2014;7(1):143-56. http://dx.doi.org/10.1586/17474086.2014.858594. PMid:24350907.

3. Gertz MA, Lacy MQ, Dispenzieri A. Amyloidosis. Hematol Oncol Clin North Am. 1999;13(6):1211-33, ix. http://dx.doi.org/10.1016/S0889-8588(05)70122-2. PMid:10626146.

4. Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol. 1995;32(1):45-59. PMid:7878478.

5. Kyle RA, Greipp PR. Amyloidosis (AL). Clinical and laboratory features in 229 cases. Mayo Clin Proc. 1983;58(10):665-83. PMid:6353084.

6. Pinney JH, Lachmann HJ. Systemic AA amyloidosis. Subcell Biochem. 2012;65:541-64. http://dx.doi.org/10.1007/978-94-007-5416-4_20. PMid:23225016.

7. Park MA, Mueller PS, Kyle RA, Larson DR, Plevak MF, Gertz MA. Primary (AL) hepatic amyloidosis: clinical features and natural history in 98 patients. Medicine. 2003;82(5):291-8. http://dx.doi.org/10.1097/01.md.0000091183.93122.c7. PMid:14530778.

8. Lovat LB, Persey MR, Madhoo S, Pepys MB, Hawkins PN. The liver in systemic amyloidosis: Insights from 123I serum amyloid P component scintigraphy in 484 patients. Gut. 1998;42(5):727-34. http://dx.doi.org/10.1136/gut.42.5.727. PMid:9659172.

9. Ebert EC, Nagar M. Gastrointestinal manifestations of amyloidosis. Am J Gastroenterol. 2008;103(3):776-87. http://dx.doi.org/10.1111/j.1572-0241.2007.01669.x. PMid:18076735.

10. Girnius S, Seldin DC, Skinner M, et al. Hepatic response after high-dose melphalan and stem cell transplantation in patients with AL amyloidosis associated liver disease. Haematologica. 2009;94(7):1029-32. http://dx.doi.org/10.3324/haematol.2008.001925. PMid:19454500.

11. Park MA, Mueller PS, Kyle RA, Larson DR, Plevak MF, Gertz MA. Primary (AL) hepatic amyloidosis: clinical features and natural history in 98 patients. Medicine (Baltimore). 2003;82(5):291-8. http://dx.doi.org/10.1097/01.md.0000091183.93122.c7. PMid:14530778.

12. Gertz MA, Kyle RA. Hepatic amyloidosis (primary [AL], immunoglobulin light chain): the natural history in 80 patients. Am J Med. 1988;85(1):73-80. http://dx.doi.org/10.1016/0002-9343(88)90505-0. PMid:3389383.

13. Buck FS, Koss MN. Hepatic amyloidosis: morphologic differences between systemic AL and AA types.Hum Pathol. 1991;22(9):904-7. http://dx.doi.org/10.1016/0046-8177(91)90180-W. PMid:1916751.

14. Levine RA. Amyloid disease of the liver. Correlation of clinical, functional and morphologic features in forty-seven patients. Am J Med. 1962;33(3):349-57. http://dx.doi.org/10.1016/0002-9343(62)90231-0. PMid:14464647.

15. Kyle RA, Bayed ED. Amyloidosis: review of 236 cases. Medicine (Baltimore). 1975;54(4):271-99. http://dx.doi.org/10.1097/00005792-197507000-00001. PMid:1152671.

16. Aramaki T, Terada H, Okumura H, et al. Portal hypertension secondary to intrahepatic arterio-portal shunt in primary amyloidosis: a case report. Gastroenterol Jpn. 1989;24(4):410-3. PMid:2777017.

17. Norero B, Pérez-Ayuso RM, Duarte I, et al. Portal hypertension and acute liver failure as uncommon manifestations of primary amyloidosis. Ann Hepatol. 2014;13(1):142-9. PMid:24378278.

18. Wang YD, Zhao CY, Yin HZ. Primary hepatic amyloidosis: a mini literature review and five cases report. Ann Hepatol. 2012;11(5):721-7. PMid:22947537.

19. Lee SS, Hadengue A, Girod C, Braillon A, Lebrec D. Reduction of intrahepatic vascular space in the pathogenesis of portal hypertension. In vivo and in vitro studies in the rat. Gastroenterology. 1987;93(1):157-61. PMid:3582902.

20. Bion E, Brenard R, Pariente EA, et al. Sinusoidal portal hypertension in hepatic amyloidosis. Gut. 1991;32(2):227-30. http://dx.doi.org/10.1136/gut.32.2.227. PMid:1864548.

21. Serra L, Poppi MC, Criscuolo M, Zandomeneghi R. Primary systemic amyloidosis with giant hepatomegaly and portal hypertension: a case report and a review of the literature. Ital J Gastroenterol. 1993;25(8):435-8. PMid:8286779.

22. Levy M, Polliack A, Lender M. The liver in amyloidosis. Digestion. 1974;10(1):40-51. http://dx.doi.org/10.1159/000197521. PMid:4847635.

23. Gregg J, Herskovic T, Bartholomew L. Ascites in systemic amyloidosis. Arch Intern Med. 1965;116(4):605-10. http://dx.doi.org/10.1001/archinte.1965.03870040119024. PMid:5835364.

24. Pozzi C, Locatelli F. Kidney and liver involvement in monoclonal light chain disorders. Semin Nephrol. 2001;22(4):319-30. PMid:12118397.

25. Gertz MA, Leung N, Lacy MQ, et al. Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney. Nephrol Dial Transplant. 2009;24(10):3132-7. http://dx.doi.org/10.1093/ndt/gfp201. PMid:19403931.

26. Sezer O, Eucker J, Jakob C, Possinger K. Diagnosis and treatment of AL amyloidosis. Clin Nephrol. 2000;53(6):417-23. PMid:10879660.

27. Dubrey SW, Hawkins PN, Falk RH. Amyloid diseases of the heart: assessment, diagnosis, and referral. Heart. 2011;97(1):75-84. http://dx.doi.org/10.1136/hrt.2009.190405. PMid:21148582.

28. Reichling JJ, Kaplan MM. Clinical use of serum enzymes in liver disease. Dig Dis Sci. 1988;33(12):1601-14. http://dx.doi.org/10.1007/BF01535953. PMid:2904353.

29. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia. 2009;23(1):3-9. http://dx.doi.org/10.1038/leu.2008.291. PMid:18971951.

30. Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538-48. http://dx.doi.org/10.1016/S1470-2045(14)70442-5. PMid:25439696.

31. Campos E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasm and beyond: evolving concepts and approached applied. Blood. 2011;117(19):5019. http://dx.doi.org/10.1182/blood-2011-01-293050. PMid:21300984.

32. Palladini G, Russo P, Bosoni T, et al. Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine. Clin Chem. 2009;55(3):499-504. http://dx.doi.org/10.1373/clinchem.2008.117143. PMid:19131635.

33. Tan SY, Pepys MB, Hawkins PN. Treatment of amyloidosis. Am J Kidney Dis. 1995;26(2):267-85. http://dx.doi.org/10.1016/0272-6386(95)90647-9. PMid:7645531.

34. Peters RA, Koukoulis G, Gimson A, Portmann B, Westaby D, Williams R. Primary amyloidosis and severe intrahepatic cholestatic jaundice. Gut. 1994;35(9):1322-52. http://dx.doi.org/10.1136/gut.35.9.1322. PMid:7959246.

5773d0785ce02aec41000000 autopsy Articles

Autops Case Rep

Share this page
Page Sections